> Strategic Advisory

Pharmaceutical pricing consulting, built on our own data

When a launch, an HTA submission or a policy change puts a date on your pricing decision, you need an answer you can defend. Our senior pricing and market access consultants start every project from GPI’s own pricing, reimbursement and HTA data, and work with pharmaceutical and biotech teams from early pipeline to post-launch.

GPI Strategic Advisory
End-to-end pharmaceutical consulting solutions

Is a pricing or market access deadline coming up?

Most of our projects start with a date in the diary. If one of these sounds familiar, we should talk.

  • A launch is 12 to 18 months away and there is no agreed price corridor or launch sequence.

  • An HTA submission or PICO scoping is coming up.

  • Loss of exclusivity is approaching and you need a pricing response across several markets.

  • A policy shift, such as MFN effects travelling through international reference pricing, or changes to how the NHS commissions and contracts locally.

  • Procurement has issued an RFP for pricing research and needs a specialist bid.

Services offered

Our pharmaceutical pricing consulting projects​

Four types of project make up most of our work. Each has a typical length, so you can plan back from your deadline.

Launch pricing strategy

Price corridors, IRP and MFN scenario modelling and launch sequencing, showing where to launch first and how each market affects your price.

Primary pricing research

Willingness-to-pay and price sensitivity research with payers and HCPs, using conjoint, price-elasticity or IDI-based designs, light-touch or comprehensive.

Market access and payer strategy

Payer IDIs, HTA and PICO strategic assessments, and UK local contracting strategy, built around the evidence payers will look for.

Rapid pricing assessment

Analogue-based benchmarking for an early price range on an asset or opportunity, for pipeline reviews and BD&L decisions, in 2 to 4 weeks.

Expert, pharmaceutical strategic consulting tailored to your needs

GPI Horizon

GPI Consulting and GPI Horizon

GPI Horizon gives an evidence-backed starting point for pricing an early-stage asset. Teams compare several TPP scenarios in one place, with evidence set against analogues across 20 to 30+ payer-validated clinical and commercial criteria. It is designed to sit alongside other research.

When a GPI Horizon result raises a strategic question, such as how to sequence a launch or what a TPP scenario means for the price corridor, our consultants take it further using the same data. A rapid pricing assessment uses the same analogue approach and takes 2 to 4 weeks.

Pharmaceutical consulting process

How a GPI Consulting project runs

Our systematic consulting approach ensures comprehensive analysis and actionable recommendations for your most complex pharmaceutical pricing and market access challenges.

Introductory call

A brief call to understand the decision, the deadline and the markets in scope.

Scoping

We propose a scope, with a light-touch or comprehensive option where it fits, and agree it with you.

Analysis

The work starts from GPI’s own data, with primary research or payer input where the project needs it.

Delivery

We deliver within the agreed timeline, with recommendations and the evidence behind them.

Who we work with

Our pharmaceutical pricing consulting clients range from specialty pharma start-ups launching their first product to mid-size and rare disease biotechs and the global and affiliate teams of large pharma companies. We also work with companies in vaccines, plasma-derived products, clinical nutrition and drug-device combinations.

We usually work with Heads of Pricing, Global Pricing and Market Access Directors, Market Access Leads, country affiliate teams, and BD&L and commercial strategy teams.

Our solutions

How GPI Consulting works

Every project starts from GPI’s pricing, reimbursement and HTA data: 200 million+ data points across 60+ pricing markets, 100+ IRP markets and 30+ HTA markets, with 95% data completeness across covered markets. You don’t need to buy data separately before the work begins.

Senior people lead the work

Senior pricing and market access consultants lead every engagement. In the words of one client, Pfizer, GPI is “always ready to listen, flexible, available, and amenable to all business needs”.

Not every question needs a 14-week study. We scope each project to the decision in front of you. For a recent willingness-to-pay project, we offered a light-touch design and a comprehensive one, so the client could match the method to their budget.

You can work with GPI Consulting without a GPI Pulse or GPI Horizon subscription. If you want to keep tracking prices, indications and HTA outcomes after a project, platform access is available.

What our clients say
Schedule consultation

Let’s connect

Connect with our experts for a free consultation and tailored solutions.

Call us on +44 (0) 203 369 0039 or fill out our form, and we’ll contact you within one business day.

FAQ

FAQs

GPI Consulting provides pharmaceutical pricing consulting and market access strategy. Our four main projects are launch pricing strategy, primary pricing research, market access and payer strategy, and rapid pricing assessments. Every project starts from GPI’s own pricing, reimbursement and HTA data.

It depends on the project. A rapid pricing assessment takes 2 to 4 weeks. Launch pricing strategy usually takes 8 to 10 weeks, market access and payer strategy 8 to 12 weeks, and primary pricing research 10 to 14 weeks, depending on fieldwork.

No. You can work with GPI Consulting without a platform subscription. Clients who want to keep tracking prices, indications and HTA outcomes after a project can add platform access.

Our consultants work from GPI’s own published pricing, reimbursement and HTA data: 200 million+ data points across 60+ pricing markets, 100+ IRP markets and 30+ HTA markets. Our data covers published prices, not confidential net prices.

GPI Horizon gives an evidence-backed starting point for pricing an early-stage asset and lets teams compare TPP scenarios in one place. When that raises a strategic question, such as launch sequencing or what a scenario means for the price corridor, our consultants take it further using the same data.

Insights & success stories

Expert strategies, industry trends & real results

Stay ahead with the latest business insights, success stories, and industry trends. Explore expert advice, real-world case studies, and actionable strategies to drive growth and innovation in your business.
Germany 15.5% rebate

Germany’s 15.5% rebate: what the BStabG means for launch pricing and IRP

Germany’s 15.5% rebate on patented medicines takes effect on 1

gene therapy JCA

The First Gene Therapy JCA: Absence of Evidence Versus Evidence of Absence

Gene therapy JCA submissions face a distinct methodological test, and

pre-launch price forecasting

Can We Predict Pricing Potential Before Launch? Putting GPI Horizon to the Test

Pre-launch price forecasting for rare disease assets was tested against